{"prompt": "['GB001, Inc.', 'GB001', 'Protocol GB001-2101', 'Version 5.0, 16 Apr 2020', 'Section # and Name', 'Description of Change', 'Brief Rationale', 'obtaining historical medical', 'records when necessary.', 'Section 4.2.1 Study Population;', 'Add aspirin-exacerbated', 'Remove subjects with', 'Section 5.2 Exclusion Criteria', 'respiratory disease (AERD)', 'AERD to maintain a more', 'exclusion criterion.', 'homogeneous study', 'population.', 'Section 5.2 Exclusion Criteria', 'Text around ECG assessment', 'This modification was made', 'was updated.', 'to improve clarity that ECG', 'assessment could be', 'repeated.', 'Section 5.2 Exclusion Criteria', 'Text was added to exclude', 'This clarification was made', 'smoking of any substance.', 'to include marijuana, its', 'components, and any other', 'substances which may be', 'smoked.', 'Section 5.3 Randomization Criteria;', 'Added criterion for subjects', 'Clarification on timing of', 'Section 8 Study Assessments and', 'who experience an', 'randomization for subjects', 'Procedures;', 'exacerbation.', 'who experience an', 'Section 8.3.7 Disease-Related Events', 'Added definition of an', 'exacerbation. Definition was', 'exacerbation and clarification', 'added to characterize', 'and/or Disease-Related Outcomes Not', 'Qualifying as AEs or SAEs', 'regarding adverse event', 'worsening of disease', 'qualification.', '(exacerbations) that may', 'occur during the study.', 'Section 5.4 Screen or Run-In Failures', 'Text added to clarify', 'Clarification on Run-in', 'designation of Run-in failure.', 'failure definition for this', 'study.', 'Section 6.3.3 Unblinding of an', 'Text added to clarify', 'Clarification of procedures', 'Individual Subject;', 'conditions for unblinding.', 'to protect samples and data', 'Section 9.5 Interim Analyses', 'for unblinding.', 'Section 7.1.1 Pregnancy', 'Updated text on Follow-up', 'Clarification on procedures', 'visit.', 'if the subject who becomes', 'pregnant.', 'Section 7.2 Subject Withdrawal from', 'Updated text to provide', 'Clarification on reasons for', 'the Study', 'further clarity.', 'subject withdrawal from', 'study.', 'Section 8 Study Assessments and', 'Changed order of assessments', 'Arranged assessments such', 'Procedures', 'that efficacy assessments', 'follow the ordering of', 'endpoints.', 'Section 8.6.3 RNA Transcriptome', 'Text was updated.', 'Clarification that not all', 'Research', 'samples may be analyzed.', '89', 'CONFIDENTIAL']['GB001, Inc.', 'GB001', 'Protocol GB001-2101', 'Version 5.0, 16 Apr 2020', 'Section # and Name', 'Description of Change', 'Brief Rationale', 'Section 10.10 Appendix 10:', 'Clarification in reference to a', 'Replaced company name', 'Prohibited Medications and', 'medication.', '(Optinose) with trade name', 'Treatments', '(XHANCE).', 'Global Change', 'Minor revisions to text.', 'Typographical errors were', 'corrected.', '90', 'CONFIDENTIAL']['GB001, Inc.', 'GB001', 'Protocol GB001-2101', 'Version 5.0, 16 Apr 2020', '11.', 'REFERENCES', 'Bachert C, Sousa AR. Lund JV, et al. Reduced need for surgery in severe nasal polyposis with', 'mepolizumab: Randomized trial. J Allergy Clin Immunol 2017;140:1024-1031', 'Bachert C, Mannent L, Naclerio RM, et al. Effect of subcutaneous dupilumab on nasal polyp', 'burden in patients with chronic sinusitis and nasal polyposis: a randomized clinical trial. JAMA', '2016;315:469-479.', 'Bj\u00f6rnsson, ES. Hepatotoxicity by Drugs: The Most Common Implicated Agents. Int J Mol Sci.', '2016;17(2):224.', 'Collins JG. Prevalence of selected chronic conditions: United States, 1990-1992. Vital Health', 'Stat 1997;194:1-89.', 'Crombruggen K, Zhang N, Gevaert P, Tomassen P, Bachert C. Pathogenesis of chronic', 'rhinosinusitis: Inflammation. J Allergy Clin Immunol 2011;128:728-732.', 'Doty RL, Shaman P, Kimmelman CP, Dann MS. University of Pennsylvania Smell Identification', 'Test: a rapid quantitative olfactory function test for the clinic. Laryngoscope 1984;94:176-178.', 'EMA, Points to consider on implications of Coronavirus disease (COVID-19) on methodological', 'aspects of ongoing clinical trials. Amsterdam, The Netherlands: Committee for Human', 'Medicinal Products; March 2020.', 'FDA, Guidance for Industry. Drug-Induced Liver Injury: Premarketing Clinical Evaluation.', 'Rockville, MD: Center for Drug Evaluation and Research, Food and Drug Administration, US', 'Dept of Health and Human Services; July 2009.', 'FDA, FDA Guidance on Conduct of Clinical Trials of Medical Products during COVID-19', 'Pandemic. Rockville, MD: Center for Drug Evaluation and Research, Food and Drug', 'Administration, US Dept of Health and Human Services; April 2020.', 'Ferguson BJ. Categorization of eosinophilic chronic rhinosinusitis. Curr Opin Otolaryngol Head', 'Neck Surg 2004;12:237-242.', 'Fokkens W, Lund V, Mullol J. European position paper on rhinosinusitis and nasal polyps 2007.', 'Rhinol Suppl 2007;20:1-136.', 'Hastan D, Fokkens WJ, Bachert C, et al. Chronic rhinosinusitis in Europe - an underestimated', 'disease. A GA(2)LEN study. Allergy 2011;9:1216-1223.', 'Health Canada, Management of clinical trials during the COVID-19 pandemic: Notice to clinical', 'trial sponsors. 2020. https://www.canada.ca/en/health-canada/services/drugs-health', 'products/drug-products/announcements/management-clinical-trials-during-covid-19-', 'pandemic.html Accessed April 13, 2020.', 'Ho J, Hamizan WA, Alvarado R, et al. Systemic predictors of eosinophilic chronic rhinosinusitis.', 'Am J Rhinol Allergy :018;32:252-257.', 'Hopkins C, Gillett S, Slack R, Lund VJ, Browne JP. Psychometric validity of the 22- item', 'sinonasal outcome test. Clin Otolaryngology 2009;34:447-454.', '91', 'CONFIDENTIAL']\n\n###\n\n", "completion": "END"}